The vaginal acquisition and dissemination of HIV-1 infection in a novel transgenic mouse model is facilitated by coinfection with herpes simplex virus 2 and is inhibited by microbicide treatment

Journal of Virology

Volumn 89, Issue 18, 2015, Pages 9559-9570

  Seay, Kieran ^a   Khajoueinejad, Nazanin ^a   Zheng, Jian Hua ^a   Kiser, Patrick ^b   Ochsenbauer, Christina ^c   Kappes, John C ^c,d   Herold, Betsy ^a   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Northwestern University   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYCLIN T1; LUCIFERASE; TENOFOVIR; TENOFOVIR DISOPROXIL; AGENTS USED INTRAVAGINALLY; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DENDRITIC CELL; ENVELOPE GENE; FEMALE; GENE EXPRESSION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; INFECTION PREVENTION; LYMPHOCYTIC INFILTRATION; MIXED INFECTION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VAGINITIS; VIRAL CONTAMINATION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS STRAIN; ANIMAL; COINFECTION; DISEASE MODEL; GENETICS; HERPES GENITALIS; HIV INFECTIONS; IMMUNOLOGY; MALE; PATHOLOGY; VAGINA; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; COINFECTION; DISEASE MODELS, ANIMAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICE; MICE, TRANSGENIC; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84940544060     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01326-15     Document Type: Article

References (65)

1. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805-812, A. http://dx.doi.org/10.2471/BLT.07 .046128.
2. Smith JS, Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186(Suppl 1):S3-28. http://dx.doi.org/10.1086/343739.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168- 1174. http://dx.doi.org/10.1126/science.1193748.
4. Nixon B, Jandl T, Teller RS, Taneva E, Wang Y, Nagaraja U, Kiser PF, Herold BC. 2014. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother 58:1153- 1160. http://dx.doi.org/10.1128/AAC.01818-13.
5. Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow R, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP, Corey L, Network NHVT. 2011. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 57:238-244. http://dx.doi.org/10.1097/QAI.0b013e31821acb5.
6. Chen L, Jha P, Stirling B, Sgaier SK, Daid T, Kaul R, Nagelkerke N. 2007. Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS One 2:e1001. http://dx.doi.org/10.1371/journal.pone .0001001.
7. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83. http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7.
8. Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Paranjape RS, Divekar AD, Gangakhedkar RR, Ghate MV, Bollinger RC, Mehendale SM. 2003. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 187:1513-1521. http://dx.doi.org/10.1086/368357.
9. Wasserheit JN. 1992. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 19:61-77.
10. Feng Z, Qiu Z, Sang Z, Lorenzo C, Glasser J. 2013. Modeling the synergy between HSV-2 and HIV and potential impact of HSV-2 therapy. Math Biosci 245:171-187. http://dx.doi.org/10.1016/j.mbs.2013.07.003.
11. Ferreira VH, Kafka JK, Kaushic C. 2014. Influence of common mucosal co-factors on HIV infection in the female genital tract. Am J Reprod Immunol 71:543-554. http://dx.doi.org/10.1111/aji.12221.
12. Nixon B, Fakioglu E, Stefanidou M, Wang Y, Dutta M, Goldstein H, Herold BC. 2014. Genital herpes simplex virus type 2 infection in humanized HIV-transgenic mice triggers HIV shedding and is associated with greater neurological disease. J Infect Dis 209:510-522. http://dx.doi.org /10.1093/infdis/jit472.
13. Rollenhagen C, Lathrop MJ, Macura SL, Doncel GF, Asin SN. 2014. Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides. Mucosal Immunol 7:1165-1174. http://dx.doi.org/10.1038/mi .2014.3.
14. Martinelli E, Tharinger H, Frank I, Arthos J, Piatak M, Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M. 2011. HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog 7:e1002109. http://dx.doi.org/10.1371/journal.ppat.1002109.
15. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R. 2007. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS 21:589-598. http://dx.doi.org/10.1097/QAD.0b013e328012b896.
16. Stefanidou M, Ramos I, Mas Casullo V, Trepanier JB, Rosenbaum S, Fernandez-Sesma A, Herold BC. 2013. Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol 87:1443-1453. http://dx.doi.org/10.1128/JVI.01302-12.
17. Denton PW, Garcia JV. 2012. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 20:268-274. http://dx.doi.org/10.1016/j.tim.2012.03.007.
18. Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H. 2013. Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy. PLoS One 8:e63537. http://dx.doi.org/10.1371/journal.pone.0063537.
19. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666. http://dx.doi.org/10 .1038/381661a0.
20. Imai K, Asamitsu K, Victoriano AF, Cueno ME, Fujinaga K, Okamoto T. 2009. Cyclin T1 stabilizes expression levels of HIV-1 Tat in cells. FEBS J 276:7124-7133. http://dx.doi.org/10.1111/j.1742-4658.2009.07424.x.
21. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451- 462. http://dx.doi.org/10.1016/S0092-8674(00)80939-3.
22. Wimmer J, Fujinaga K, Taube R, Cujec TP, Zhu Y, Peng J, Price DH, Peterlin BM. 1999. Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology 255:182-189. http://dx.doi.org/10.1006/viro .1998.9589.
23. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Masse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM. 2015. Tenofovir-based preexposure prophylaxis for HIV infection among African women.NEngl J Med 372:509- 518. http://dx.doi.org/10.1056/NEJMoa1402269.
24. Rees H, Delany-Moretlwe S, Baron D, Lombard C, Gray G, Myer L, Panchia R, Schwartz J, Doncel G. 2015. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women, abstr 26LB. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 23 to 26 February 2015.
25. Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS.A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection. Expert Opin Investig Drugs 21:695-715. http://dx.doi.org/10.1517/13543784.2012.667072.
26. Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty JF, Yale K, Poblenz M, Kearney BP, Zhong L, Coakley DF, Blanche S, Bresson JL, Zuckerman JA, Zeichner SL. 2004. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate inhumanim-munodeficiency virus-infected children. Antimicrob Agents Chemother 48: 124-129. http://dx.doi.org/10.1128/AAC.48.1.124-129.2004.
27. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob Agents Chemother 42:612-617.
28. Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC. 2012. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother 67:1730-1738. http://dx.doi.org/10.1093/jac /dks097.
29. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF. 2013. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A 110:16145-16150. http://dx.doi.org/10.1073 /pnas.1311355110.
30. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefiori DC, Kappes JC, Ochsenbauer C. 2010. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13. http://dx.doi.org/10.1016/j.virol.2010.08.028.
31. Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M, Kappes JC, Ngauy V, Marovich M, Michael N, Ochsenbauer C, Montefiori DC, Polonis VR. 2012. The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One 7:e29454. http://dx.doi.org/10.1371/journal.pone.0029454.
32. Chenine AL, Wieczorek L, Sanders-Buell E, Wesberry M, Towle T, Pillis DM, Molnar S, McLinden R, Edmonds T, Hirsch I, O'Connell R, McCutchan FE, Montefiori DC, Ochsenbauer C, Kappes JC, Kim JH, Polonis VR, Tovanabutra S. 2013. Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone. PLoS One 8:e76104. http://dx.doi.org/10.1371/journal.pone.0076104.
33. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 88:2489-2507. http://dx.doi.org/10.1128/JVI.02853-13.
34. + T-lymphoblastoid cell assay system. PLoS One 8:e77756. http://dx.doi.org/10.1371/journal.pone.0077756.
35. Naarding MA, Fernandez N, Kappes JC, Hayes P, Ahmed T, Icyuz M, Edmonds TG, Bergin P, Anzala O, Hanke T, Clark L, Cox JH, Cormier E, Ochsenbauer C, Gilmour J. 2014. Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses. J Immunol Methods 409:161-173. http://dx.doi.org/10.1016/j.jim.2013.11 .021.
36. Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. 2012. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol 86:2715- 2728. http://dx.doi.org/10.1128/JVI.06157-11.
37. Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD. 2013. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 110:13540-13545. http: //dx.doi.org/10.1073/pnas.1304985110.
38. Sarzotti-Kelsoe M, Daniell X, Todd CA, Bilska M, Martelli A, LaBranche C, Perez LG, Ochsenbauer C, Kappes JC, Rountree W, Denny TN, Montefiori DC. 2014. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods 409:147-160. http://dx.doi.org/10.1016/j.jim.2014.02.013.
39. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, Otto P, Zimmerman K, Vidugiris G, Machleidt T, Robers MB, Benink HA, Eggers CT, Slater MR, Meisenheimer PL, Klaubert DH, Fan F, Encell LP, Wood KV. 2012. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol 7:1848-1857. http://dx.doi.org/10.1021/cb3002478.
40. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early acquired infections in Southern Africa. J Virol 80:11776-11790. http://dx.doi.org/10.1128/JVI.01730-06.
41. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW. 2005. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21:845-853. http://dx.doi.org/10.1089/aid .2005.21.845.
42. / (RAG-hu) mice. Virology 373:342- 351. http://dx.doi.org/10.1016/j.virol.2007.11.020.
43. Fidel PL, Jr, Wolf NA, KuKuruga MA. 1996. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 64:3793-3799.
44. Iijima N, Mattei LM, Iwasaki A. 2011. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 108:284-289. http://dx.doi.org/10.1073/pnas.1005201108.
45. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. 2008. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5:e16. http://dx.doi.org/10.1371/journal.pmed.0050016.
46. Hendrickson BA, Guo J, Brown I, Dennis K, Marcellino D, Hetzel J, Herold BC. 2000. Decreased vaginal disease in J-chain-deficient mice following herpes simplex type 2 genital infection. Virology 271:155-162. http://dx.doi.org/10.1006/viro.2000.0303.
47. Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, Doncel GF, Herold BC. 2011. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One 6:e27675. http://dx.doi.org/10.1371/journal .pone.0027675.
48. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ. 1996. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 2:1084-1089. http://dx.doi.org/10.1038/nm1096-1084.
49. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210. http://dx.doi.org/10.1038/72318.
50. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223. http://dx.doi.org/10.1038/nature08757.
51. Villadangos JA, Cardoso M, Steptoe RJ, van Berkel D, Pooley J, Carbone FR, Shortman K. 2001. MHC class II expression is regulated in dendritic cells independently of invariant chain degradation. Immunity 14:739-749. http://dx.doi.org/10.1016/S1074-7613(01)00148-0.
52. Wilflingseder D, Mullauer B, Schramek H, Banki Z, Pruenster M, Dierich MP, Stoiber H. 2004. HIV-1-induced migration of monocyte-derived dendritic cells is associated with differential activation of MAPK pathways. J Immunol 173:7497-7505. http://dx.doi.org/10.4049/jimmunol.173.12.7497.
53. Ward H, Ronn M. 2010. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 5:305-310. http: //dx.doi.org/10.1097/COH.0b013e32833a8844.
54. Siveke JT, Hamann A. 1998. T helper 1 and T helper 2 cells respond differentially to chemokines. J Immunol 160:550-554.
55. Schall TJ, Bacon KB. 1994. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 6:865-873. http://dx.doi.org/10.1016 /0952-7915(94)90006-X.
56. + T cells using a combination of cytokines. J Exp Med 188:83-91. http://dx.doi.org/10.1084/jem.188.1.83.
57. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A 86:2365-2368. http://dx.doi.org/10.1073/pnas.86.7.2365.
58. Seth S, Oberdorfer L, Hyde R, Hoff K, Thies V, Worbs T, Schmitz S, Forster R. 2011. CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions. J Immunol 186:3364-3372. http://dx.doi.org/10.4049 /jimmunol.1002598.
59. Masurier C, Salomon B, Guettari N, Pioche C, Lachapelle F, Guigon M, Klatzmann D. 1998. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol 72:7822-7829.
60. Kollias CM, Huneke RB, Wigdahl B, Jennings SR. 2015. Animal models of herpes simplex virus immunity and pathogenesis. J Neurovirol 21:8- 23. http://dx.doi.org/10.1007/s13365-014-0302-2.
61. Bieniasz PD, Cullen BR. 2000. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol 74:9868-9877. http: //dx.doi.org/10.1128/JVI.74.21.9868-9877.2000.
62. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV. 2011. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 85:7582-7593. http://dx.doi.org/10 .1128/JVI.00537-11.
63. Ghebremichael M, Habtzgi D, Paintsil E. 2012. Deciphering the epidemic synergy of herpes simplex virus type 2 (HSV-2) on human immunodeficiency virus type 1 (HIV-1) infection among women in sub- Saharan Africa. BMC research notes 5:451. http://dx.doi.org/10.1186 /1756-0500-5-451.
64. Lihana RW, Ssemwanga D, Abimiku A, Ndembi N. 2012. Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev 14:83-100.
65. Hatziioannou T, Evans DT. 2012. Animal models for HIV/AIDS research. Nat Rev Microbiol 10:852-867. http://dx.doi.org/10.1038/nrmicro2911.